Drug Profile
Irbesartan/propagermanium - Dimerix Bioscience
Alternative Names: DMX-200; Propagermanium/irbesartanLatest Information Update: 19 Oct 2023
Price :
$50
*
At a glance
- Originator Dimerix Bioscience
- Class Biphenyl compounds; Organometallic compounds; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III COVID-19 pneumonia; Focal segmental glomerulosclerosis
- Phase II COVID 2019 infections; Diabetic nephropathies; Renal failure
Most Recent Events
- 04 Oct 2023 DMX 200 licensed to ADVANZ PHARMA in Europe (Economic Area), UK, Switzerland, Canada, Australia, and New Zealand
- 04 Oct 2023 ADVANZ PHARMA announces intention to submit marketing approval application for Focal segmental glomerulosclerosis
- 02 Jan 2023 Dimerix Bioscience plans accelerated marketing approval for Irbesartan/propagermanium in Focal segmental glomerulosclerosis